Madrigal Pharmaceuticals, Inc.
MDGL
शेयरों में रैंक
#1943
Madrigal Pharmaceuticals, Inc. is a biopharmaceutical company in the clinical... Madrigal Pharmaceuticals, Inc. is a biopharmaceutical company in the clinical development phase, concentrating its efforts on discovering and commercializing innovative treatments for cardiovascular, metabolic, and liver disorders. Its most advanced drug candidate, resmetirom, functions as a liver-targeted selective thyroid hormone receptor-ß agonist, currently undergoing late-stage (Phase III) clinical trials for managing non-alcoholic steatohepatitis (NASH). The company's pipeline also features MGL-3745, which serves as a secondary or backup compound to resmetirom. Madrigal holds a collaborative agreement with Hoffmann-La Roche, encompassing research, development, and commercialization activities. The company's operations are based out of West Conshohocken, Pennsylvania.
शेयर मूल्य
$469.52
मार्केट कैप
$10.85B
बदलाव (1 दिन)
5.02%
बदलाव (1 वर्ष)
6.72%
देश
US
व्यापार Madrigal Pharmaceuticals, Inc. (MDGL)
श्रेणी
Healthcare
Madrigal Pharmaceuticals, Inc. (MDGL) के लिए कमाई
Jun 2026 में कमाई TTM: $-325.10M
Madrigal Pharmaceuticals, Inc. की नवीनतम वित्तीय रिपोर्टों के अनुसार, कंपनी की वर्तमान कमाई $-325.10M है। 2023 में कंपनी ने $-373.63M की कमाई की, जो 2022 की कमाई $-295.35M के की तुलना में कमी है। इस पृष्ठ पर दिखाई गई कमाई ब्याज और कर से पहले की कमाई है, जिसे EBIT कहा जाता है।
Madrigal Pharmaceuticals, Inc. के लिए कमाई का इतिहास 2001 से 2026 तक
प्रत्येक वर्ष के अंत में कमाई
| वर्ष | कमाई | परिवर्तन |
|---|---|---|
| 2026 (TTM) | $-325.10M | -30.22% |
| 2024 | $-465.89M | 24.69% |
| 2023 | $-373.63M | 26.50% |
| 2022 | $-295.35M | 22.12% |
| 2021 | $-241.85M | 19.58% |
| 2020 | $-202.24M | 140.92% |
| 2019 | $-83.95M | 155.85% |
| 2018 | $-32.81M | 5.32% |
| 2017 | $-31.15M | 18.06% |
| 2016 | $-26.39M | -61.57% |
| 2015 | $-68.67M | -20.30% |
| 2014 | $-86.16M | -4.47% |
| 2013 | $-90.19M | 43.64% |
| 2012 | $-62.79M | 32.52% |
| 2011 | $-47.38M | 26.46% |
| 2010 | $-37.47M | -147.37% |
| 2009 | $79.09M | -185.39% |
| 2008 | $-92.62M | 45.87% |
| 2007 | $-63.50M | 7.38% |
| 2006 | $-59.13M | -14.14% |
| 2005 | $-68.86M | 49.92% |
| 2004 | $-45.93M | 64.77% |
| 2003 | $-27.88M | -48.71% |
| 2002 | $-54.35M | 0.00% |
| 2001 | 0.00 | 0.00% |
समान कंपनियों या प्रतियोगियों की कमाई
| कंपनी | कमाई | कमाई में अंतर | देश |
|---|---|---|---|
| $5.27B | -1,722.57% |
US
|
|
| $-3.09B | 849.57% |
US
|
|
| $-4.02B | 1,135.39% |
AU
|
|
| - | - |
CH
|
|
| $1.95B | -700.02% |
NL
|
